Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 47 recruiting now early-phase tilt #108 of 28,707 conditions

Metastatic Cancer: early-phase trial registry

47 of 117 indexed Metastatic Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #108 of 28,707 conditions by registered trial count.

117 US clinical trials · 47 currently recruiting · #108 of 28,707 conditions by registered trial count

Metastatic Cancer: 117 US clinical trials tracked, 47 recruiting.

Metastatic Cancer is the subject of 117 registered US clinical trials on ClinicalTrials.gov, 47 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 87 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 11 of these trials.

Enrollment posture brief

Registry condition metastatic-cancer

OPEN 47 | RECR 40% | LATE 8 | EARLY 87 | RANK #108 | SPON 11

Nearest open-share peer: Knee Osteoarthritis (40% recruiting · 102 trials)

Triple Negative Breast Cance57.1%Metastatic Cancer (this)40%Overweight and Obesity34.5%Diabetes Mellitus, Type 132.8%Weight Loss26.1%
Open-enrollment share among volume-matched conditions near Metastatic Cancer

Metastatic Cancer lists 47 open slots (40% of 117 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Metastatic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Metastatic Cancer is recruiting above its size-band peers.

    47 of 117 indexed trials (40.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Metastatic Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 11 of 117 trials (9.4%). 80 distinct sponsors appear on at least one study for this condition label.

  3. Most Metastatic Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 54 among the 110 trials that report a genuine target (sentinel values excluded). 70 of those (63.6%) plan for fewer than 100 participants.

  4. Metastatic Cancer research is mostly interventional.

    108 interventional and 9 observational studies make up this index (92.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 154Phase 233Phase 38

Open and recent trials

117 total, page 2 of 3

ACTIVE NOT RECRUITING Phase 2 160 participants

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Xiuning Le

NCT03909334

ACTIVE NOT RECRUITING Phase 2 120 participants

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Aadi Bioscience

NCT05103358

ACTIVE NOT RECRUITING Phase 1 85 participants

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

Verastem

NCT05375994

ACTIVE NOT RECRUITING Phase 1 82 participants

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

invoX Pharma Limited

NCT04648202

ACTIVE NOT RECRUITING Phase 2 69 participants

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Memorial Sloan Kettering Cancer Center

NCT03693014

ACTIVE NOT RECRUITING 69 participants

Biomarkers of Immune-Related Toxicity

University of Colorado, Denver

NCT03409016

ACTIVE NOT RECRUITING Phase 2 64 participants

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Memorial Sloan Kettering Cancer Center

NCT00492999

ACTIVE NOT RECRUITING Phase 2 60 participants

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

University of Wisconsin, Madison

NCT04090528

ACTIVE NOT RECRUITING Phase 1 54 participants

A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer

Memorial Sloan Kettering Cancer Center

NCT05678010

ACTIVE NOT RECRUITING Phase 1 49 participants

A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer

Memorial Sloan Kettering Cancer Center

NCT05566574

ACTIVE NOT RECRUITING NA 45 participants

An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer

Memorial Sloan Kettering Cancer Center

NCT03794635

ACTIVE NOT RECRUITING Phase 1 40 participants

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

Verastem

NCT05669482

ACTIVE NOT RECRUITING NA 39 participants

A Study of Stereotactic Body Radiotherapy (SBRT) and Surgical Stabilization for People With Cancer That Has Spread to the Bone

Memorial Sloan Kettering Cancer Center

NCT05038124

ACTIVE NOT RECRUITING Phase 2 35 participants

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Glenn J. Hanna

NCT05010629

ACTIVE NOT RECRUITING Phase 2 32 participants

Metastatic Solid Cancer Clinical Trial

ImmunSYS

NCT04739618

ACTIVE NOT RECRUITING Phase 2 32 participants

A Phase 2 Trial for Patients With Metastatic Solid Cancer

Rampart Health, L.L.C.

NCT04713371

ACTIVE NOT RECRUITING NA 20 participants

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

City of Hope Medical Center

NCT02293954

ACTIVE NOT RECRUITING Phase 2 20 participants

Niraparib in Tumors Metastatic to the CNS

Massachusetts General Hospital

NCT04992013

ACTIVE NOT RECRUITING Phase 1 16 participants

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

ImmunityBio

NCT04050709

ACTIVE NOT RECRUITING Phase 1 12 participants

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

University of California, Irvine

NCT04868773

ACTIVE NOT RECRUITING Phase 2 10 participants

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

M.D. Anderson Cancer Center

NCT05335941

COMPLETED 22,517 participants

Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment

Daiichi Sankyo

NCT06557967

COMPLETED Phase 3 600 participants

Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone

Novartis

NCT00003884

COMPLETED Phase 3 501 participants

Talc in Treating Patients With Malignant Pleural Effusion

Alliance for Clinical Trials in Oncology

NCT00002622

COMPLETED NA 240 participants

Randomized Clinical Trial of a Multi-Modal Palliative Care Intervention

University of Colorado, Boulder

NCT04773639

COMPLETED Phase 3 213 participants

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Alliance for Clinical Trials in Oncology

NCT00377156

COMPLETED Phase 1 174 participants

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

ALX Oncology

NCT03013218

COMPLETED 137 participants

Quality of Life in Patients With Liver Cancer Treated With Image-Guided Therapy

Vanderbilt University

NCT00482586

COMPLETED Phase 3 135 participants

Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer

Alliance for Clinical Trials in Oncology

NCT00002716

COMPLETED Phase 2 106 participants

Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease

University of California, San Diego

NCT02843165

COMPLETED Phase 1 89 participants

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Symphogen A/S

NCT03311412

COMPLETED Phase 1 78 participants

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

Ikena Oncology

NCT04200963

COMPLETED 76 participants

Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders

Case Comprehensive Cancer Center

NCT00255671

COMPLETED Phase 2 59 participants

Heat Therapy in Treating Patients With Unresectable Primary or Metastatic Liver Cancer

M.D. Anderson Cancer Center

NCT00004136

COMPLETED NA 59 participants

Evaluation of Memory Skills in Patients Receiving Radiation Therapy for Brain Metastases

Radiation Therapy Oncology Group

NCT00007007

COMPLETED Phase 2 55 participants

Epothilone B in Treating Patients With CNS Metastases From Breast Cancer

David Peereboom, MD

NCT00450866

COMPLETED Phase 2 53 participants

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

University of Colorado, Denver

NCT03475004

COMPLETED Phase 2 49 participants

Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma

Children's Oncology Group

NCT00066365

COMPLETED Phase 2 44 participants

S0916, MLN1202 in Treating Patients With Bone Metastases

SWOG Cancer Research Network

NCT01015560

COMPLETED Phase 1 44 participants

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

PureTech

NCT04666688

COMPLETED NA 42 participants

Feasibility, Acceptability and Preliminary Effects of the Spiritual Care Assessment and Intervention

Indiana University

NCT03823313

COMPLETED Phase 1 41 participants

Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2

University of California, San Francisco

NCT00544804

COMPLETED Phase 1 40 participants

Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Alliance for Clinical Trials in Oncology

NCT00017121

COMPLETED Phase 2 35 participants

Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis

University of Texas Southwestern Medical Center

NCT00855803

COMPLETED Phase 1 30 participants

Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors

National Institutes of Health Clinical Center (CC)

NCT00093444

COMPLETED Phase 2 30 participants

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

Jonsson Comprehensive Cancer Center

NCT00024076

COMPLETED Phase 1 28 participants

Busulfan in Treating Children and Adolescents With Refractory CNS Cancer

Pediatric Brain Tumor Consortium

NCT00006246

COMPLETED Phase 2 27 participants

Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy

Northwestern University

NCT01898130

COMPLETED Phase 1 26 participants

Radiation Therapy in Treating Patients With Liver Metastases

Radiation Therapy Oncology Group

NCT00255814

COMPLETED Phase 1 25 participants

Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

City of Hope Medical Center

NCT00544284

← Previous Page 2 of 3 Next →

Phase Distribution

PhaseTrial count
Phase 1 54
Phase 2 33
Phase 3 8

Named interventions

Most-linked intervention names on Metastatic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

quality-of-life assessment Procedure
5 trials
Nivolumab Drug
5 trials
Pembrolizumab Drug
5 trials
conventional surgery Procedure
4 trials
leucovorin calcium Drug
4 trials
fluorouracil Drug
4 trials
radiofrequency ablation Procedure
3 trials
irinotecan hydrochloride Drug
3 trials

US sites by state

Facility locations filed on Metastatic Cancer trials. A trial with sites in several states counts in each.

California 41 trials
New York 30 trials
Florida 29 trials
Texas 28 trials
Illinois 19 trials
Arizona 17 trials
Massachusetts 16 trials
Michigan 15 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Metastatic Cancer page

117 registered trials, 47 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Cancer condition card totals 117 registered trials; most-linked intervention quality-of-life assessment; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.